ATE424822T1 - Tetrahydro-beta-karbolin-sulfonamid-derivate als 5-ht6-liganden - Google Patents

Tetrahydro-beta-karbolin-sulfonamid-derivate als 5-ht6-liganden

Info

Publication number
ATE424822T1
ATE424822T1 AT06818244T AT06818244T ATE424822T1 AT E424822 T1 ATE424822 T1 AT E424822T1 AT 06818244 T AT06818244 T AT 06818244T AT 06818244 T AT06818244 T AT 06818244T AT E424822 T1 ATE424822 T1 AT E424822T1
Authority
AT
Austria
Prior art keywords
tetrahydro
sulfonamide derivatives
carboline
ligands
beta
Prior art date
Application number
AT06818244T
Other languages
English (en)
Inventor
Jose Diaz-Fernandez
Ramon Merce-Vidal
Joerg Holenz
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of ATE424822T1 publication Critical patent/ATE424822T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06818244T 2005-07-28 2006-07-26 Tetrahydro-beta-karbolin-sulfonamid-derivate als 5-ht6-liganden ATE424822T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05380174A EP1747779A1 (de) 2005-07-28 2005-07-28 Tetrahydro-b-carbolinsulfonamid-Derivate als 5-HT6 Liganden

Publications (1)

Publication Number Publication Date
ATE424822T1 true ATE424822T1 (de) 2009-03-15

Family

ID=35559403

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06818244T ATE424822T1 (de) 2005-07-28 2006-07-26 Tetrahydro-beta-karbolin-sulfonamid-derivate als 5-ht6-liganden

Country Status (10)

Country Link
US (1) US8263609B2 (de)
EP (2) EP1747779A1 (de)
JP (1) JP2009502840A (de)
CN (1) CN101272785A (de)
AT (1) ATE424822T1 (de)
CA (1) CA2616729A1 (de)
DE (1) DE602006005685D1 (de)
ES (1) ES2321879T3 (de)
PT (1) PT1919475E (de)
WO (1) WO2007028460A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102005016460A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
DE102007009235A1 (de) * 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020230B1 (de) * 2007-08-01 2011-01-19 Laboratorios del Dr. Esteve S.A. Kombination von mindestens zwei 5-HT6-Liganden
AU2008302751A1 (en) * 2007-09-20 2009-03-26 D2E, Llc Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
EP2053052A1 (de) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Verfahren zur Herstellung von 6-substituiertem Imidazo[2,1-b]thiazol-5-sulfonylhalogenid
TWI443098B (zh) 2008-03-24 2014-07-01 Medivation Technologies Inc 吡啶并〔3,4-b〕吲哚及使用方法
CN102046591B (zh) * 2008-03-27 2014-12-03 格吕伦塔尔有限公司 羟甲基环己胺
ES2464102T3 (es) 2008-03-27 2014-05-30 Grünenthal GmbH Derivados de 4-aminociclohexano sustituidos
JP5529843B2 (ja) * 2008-03-27 2014-06-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換シクロヘキシルジアミン
AU2009228647B2 (en) * 2008-03-27 2013-07-04 Grunenthal Gmbh Substituted spirocyclic cyclohexane derivatives
ES2375543T3 (es) * 2008-03-27 2012-03-01 Grünenthal GmbH Derivados de espiro(5.5)undecano.
EP2116546A1 (de) 2008-05-09 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituierte N-Phenyl-2,3-dihydroimidazo[2,1-b]thiazol-5-sulfonamid-Derivative als 5-HT6-Liganden
EP2116547A1 (de) 2008-05-09 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituierte n-Imidazo[2,1-b]thiazol-5-sulfonamid-Derivative als 5-TH6-Liganden
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
CN102227431A (zh) 2008-09-29 2011-10-26 雅培制药有限公司 吲哚和二氢吲哚衍生物及其应用方法
ES2587856T3 (es) 2011-03-18 2016-10-27 Ono Pharmaceutical Co., Ltd. Derivado de tetrahidrocarbolina
CN104557664B (zh) * 2013-10-19 2020-01-21 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
CN107686510A (zh) * 2016-08-05 2018-02-13 首都医科大学 甲基四氢‑β‑咔啉‑3‑甲酰RGD肽,其合成,抗血栓作用和应用
CN107686511A (zh) * 2016-08-05 2018-02-13 首都医科大学 甲基四氢‑β‑咔啉‑3‑甲酰YIGS肽,其合成,抗血栓作用和应用
EP4208446A4 (de) * 2020-09-02 2024-10-30 Enveric Biosciences Canada Inc. Nitrierte psilocybinderivate und verwendung davon zur modulation des 5-ht2a-rezeptors und zur behandlung einer psychiatrischen erkrankung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1234567A (en) * 1915-09-14 1917-07-24 Edward J Quigley Soft collar.
AU6298196A (en) 1995-06-23 1997-01-22 Novo Nordisk A/S Tetrahydro-betacarboline derivatives and their preparation and use
HU227568B1 (en) 1997-12-24 2011-08-29 Sanofi Aventis Deutschland Indole derivatives, as inhibitors os factor xa
AU2001292898A1 (en) * 2000-09-20 2002-04-02 Brad A. Acker Substituted azepino[4,5b)indole derivatives
JP4220779B2 (ja) 2001-02-12 2009-02-04 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物
AU2002249890A1 (en) 2001-02-12 2002-08-28 Lilly Icos Llc Carboline derivatives
EP1383765B1 (de) 2001-04-25 2006-12-13 Lilly Icos LLC Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion
WO2002088101A2 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
WO2002098875A1 (en) 2001-06-05 2002-12-12 Lilly Icos Llc Carboline derivatives as pde-5 inhibitors
MXPA04003419A (es) * 2001-10-09 2004-07-08 Upjohn Co Tetrahidro y hexahidro-carbazoles sustituidos con arilsulfonilo como ligandos del receptor 5-ht-6.
TW200524864A (en) * 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
WO2006040180A1 (en) * 2004-10-14 2006-04-20 Abbott Gmbh & Co. Kg Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor

Also Published As

Publication number Publication date
EP1747779A1 (de) 2007-01-31
EP1919475B1 (de) 2009-03-11
US8263609B2 (en) 2012-09-11
ES2321879T3 (es) 2009-06-12
US20080280942A1 (en) 2008-11-13
PT1919475E (pt) 2009-05-05
HK1120725A1 (en) 2009-04-09
WO2007028460A1 (en) 2007-03-15
EP1919475A1 (de) 2008-05-14
DE602006005685D1 (de) 2009-04-23
CN101272785A (zh) 2008-09-24
JP2009502840A (ja) 2009-01-29
CA2616729A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
ATE424822T1 (de) Tetrahydro-beta-karbolin-sulfonamid-derivate als 5-ht6-liganden
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
DE60330187D1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
EA200600892A1 (ru) Новые хинолиновые производные
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
TW200509907A (en) Indol-6-yl sulfonamide derivatives, their preparation and their use in medicaments
MA26906A1 (fr) Aminoalkyl 1-lactames substituees et leur utilisation en tant qu'antagonistes du recepteur muscarinique
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
NO20060342L (no) 1-sulfonylindol derivater, deres fremstilling og deres andvendelse som 5-HT6 ligander
TW200504014A (en) Indol-5-yl sulfonamide derivatives, their preparation and their use in medicaments
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
NO20055492L (no) Anvendelse av sulfonamidderivater for fremstilling av et medikament for profylakse og/eller behandling av lidelser ved matinntak
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
DE602004021385D1 (de) Indol-4 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
ATE513810T1 (de) Aminoalkoxy-aryl-sulfonamidverbindungen und ihre verwendung als 5-ht6-liganden
DE602004016177D1 (de) Methylindole und methylpyrrolopyridine als alpha-1-adrenerge agonisten
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
EA200702199A1 (ru) Новые соединения для лечения воспалительных заболеваний
NO20060506L (no) Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1919475

Country of ref document: EP

REN Ceased due to non-payment of the annual fee